Sanofi Ventures
Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at LEK consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.
Chris currently serves on the Board of Directors for i2O Therapeutics and Minervax.
Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a BS in both Biology and Chemistry from Roger Williams University.
This person is not in any offices
Sanofi Ventures
20 followers
Sanofi Ventures is the corporate venture capital arm of Sanofi. They have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health solutions.